Extended Data Fig. 6: Prior treatment history of responders.
From: Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance
Systemic therapies administered after CRPC diagnosis in responders. Patients are ordered as per Fig. 4a. Each rectangle represents a two-month interval. All patients received androgen deprivation therapy throughout this period. Dose represents AZD5069 dose. AR-V7+ indicates the presence of AR-V7 protein expression in the pre-treatment CRPC biopsy. BD = twice daily.
